Stablepharma welcomes Sir Jonathan Van-Tam to its advisory board

The company will use Prof. Van-Tam's health expertise to advance its vaccination projects

Stablepharma, a biopharmaceutical company developing a range of next generation fridge-free vaccine products, has appointed Sir Jonathan Van-Tam, a physician and public health specialist with a clinical background in emergency medicine, anaesthesia and infectious diseases, to its advisory board.

He is an expert on respiratory viruses and pandemics and is currently part-time Senior Strategy Adviser to the University of
Nottingham School of Medicine, having stepped down from his government post around two years ago.

“We are very lucky to have Professor Van-Tam join our Advisory Board, particularly given his vast expertise within vaccinology and his outstanding leadership role as part of the government’s response to the COVID pandemic, said Ozgur Tuncer, CEO & Executive
Director, Stablepharma.
 "As we develop our pipeline of thermostable pharmaceutical products, Prof Van Tam’s knowledge and guidance will greatly advance our projects."

Professor Van-Tam’s career has also taken him to Public Health England (formerly the Health Protection Agency), the World Health Organization, as well as the pharmaceutical and vaccine industries. In the latter roles he specialised in Medical Affairs, particularly market
access and new product development.

“Vaccination not only saves lives and prevents serious disease, but it is also one of the most cost-effective public health measures
available. Adding fridge-free solutions into our repertoire, thereby reducing the global challenges of distribution and storage is potentially a great step forwards, especially in more challenging environments”, said Professor Van-Tam. ‘I am looking forward to working with
the Stablepharma team to deploy these technologies." 


You may also like